

September 9, 2013

Press Release

Mitsubishi Tanabe Pharma Corporation

Tanabe Indonesia to Construct New Production Facility in Indonesia

Osaka, Japan, September 9, 2013---Mitsubishi Tanabe Pharma Corporation (President & Representative Director, CEO: Michihiro Tsuchiya) announced today that P.T. Tanabe Indonesia, (Head Office: Special Capital Region of Jakarta, Indonesia), one of its consolidated subsidiaries, will construct a new production facility on its factory's property in Bandung. The planned facility is aimed at expanding production capability and meeting PIC/s-GMP, new GMP standards.

Since its establishment in 1970, P.T. Tanabe Indonesia has been manufacturing pharmaceutical products for supply to Indonesia and its neighboring countries. Construction of the new facility will begin in September this year, with its operation set to start in May 2015. The new facility will boost the Bandung factory's production capability by 1.75 times from the current level for major product, Herbesser[®], antihypertensive drug, and other solid preparations.

Establishing the foundation for expanded overseas operations has been set as a major business strategy under our Medium-Term Management Plan 11-15, New Value Creation. The new facility construction plan is designed for P.T. Tanabe Indonesia to expand its pharmaceutical supply to Indonesia and its neighboring countries, with the aim of reinforcing business operations in drug markets with growth potential and continuing to ensure a stable supply of high-quality pharmaceuticals.

<For further information, contact>
Corporate Communications Department
Phone: +81-6-6205-5211

<Outline of a production facility to be constructed newly>

Location: Jl. Rumah Sakit 104, Ujungberung, Bandung 40612, Indonesia

Start of construction: September 2013

Completion: August 2014

Operation is set to start in May 2015.

Scale of new facility: 3-story building (construction area: about 1,200 m²,
total floor space: about 2,800m²)

Total construction cost: about ¥800 million (planned)

Designing and construction: P.T. SMCC UTAMA INDONESIA
(Sumitomo Mitsui Construction Co., Ltd.)

External appearance:



<Outline of P.T. Tanabe Indonesia>>

- Corporate name: P.T. Tanabe Indonesia
- Representative: President Toyotaka Ozaki
- Foundation: July 1970
- Paid-in capital: 2.5 million U.S. dollars
- Equity holders: 99.6% by Mitsubishi Tanabe Pharma
- Business activities: Production and sales of pharmaceuticals
- Annual sales: about ¥2.5 billion (for the year ended in March 2013)
- Main products: Herbesser, Tanatril, Maintate, Livalo
- Production capacity: about 100 million tablets (as of the end of March 2013)
- No. of employees: 490 (as of the end of July 2013)